Published article: “Bridging gaps in clinical trial accessibility and reimbursement for large B-cell lymphoma therapies across Europe,” in HemaSphere.
This publication examines the unmet need in large B-cell lymphoma (LBCL) across Europe, focusing on how clinical innovation translates into access for patients. The analysis maps disparities in clinical trial availability and national reimbursement for EMA-approved therapies, and highlights barriers such as limited trial reach, time to access, and the underuse of real-world evidence (RWE) and patient-reported outcomes (PROs). The paper offers practical recommendations to improve adoption and ensure that standards of care are implemented consistently across health systems.
The article is co-authored by Lorna Warwick, CEO of Lymphoma Coalition, and Natacha Bolaños, Head, Membership & Alliance at Lymphoma Coalition, alongside European experts. It reflects a multidisciplinary effort that brings together clinical leaders and the patient community to connect evidence with implementation and to provide actionable guidance for clinicians, payers, policymakers, industry, and advocates.
By amplifying patient perspectives and strengthening collaboration across stakeholders, this work represents an important step toward timely and equitable access to innovative LBCL therapies.
Lymphoma Coalition extends its gratitude to HemaSphere for publishing this study and to all contributors who helped shape it.